Edition:
United Kingdom

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

16.35USD
8:59pm GMT
Change (% chg)

$-0.05 (-0.30%)
Prev Close
$16.40
Open
$16.45
Day's High
$16.70
Day's Low
$16.05
Volume
1,669,773
Avg. Vol
361,563
52-wk High
$18.40
52-wk Low
$2.85

Chart for

About

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company... (more)

Overall

Beta: 3.12
Market Cap(Mil.): $1,333.59
Shares Outstanding(Mil.): 83.61
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Sangamo Therapeutics posts Q3 loss per share $0.15

* Sangamo Therapeutics reports third quarter 2017 financial results

09 Nov 2017

BRIEF-Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400

* Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400 -- a gene-edited cell therapy candidate -- to treat beta-thalassemia

02 Oct 2017

BRIEF-Sangamo Therapeutics reports Q2 loss per share $0.17

* Sangamo Therapeutics reports second quarter 2017 financial results

09 Aug 2017

BRIEF-Sangamo Therapeutics appoints Roger Jeffs, Joseph Zakrzewski to its board

* Sangamo Therapeutics appoints Roger Jeffs, PH.D. and Joseph S. Zakrzewski to its board of directors

29 Jun 2017

BRIEF-Sangamo Therapeutics announces closing of public offering of common stock

* Sangamo Therapeutics announces closing of public offering of common stock and exercise in full of underwriters' option to purchase additional shares of common stock Source text for Eikon: Further company coverage:

26 Jun 2017

BRIEF-Sangamo announces pricing of $72.5 mln public offering of common stock

* Sangamo therapeutics announces pricing of $72.5 million public offering of common stock

21 Jun 2017

BRIEF-Sangamo Therapeutics announces proposed public offering of common stock

* Sangamo Therapeutics announces proposed public offering of common stock Source text for Eikon: Further company coverage:

20 Jun 2017

Competitors

  Price Chg
Novo Nordisk A/S (NOVOb.CO) kr.329.50 -6.90
Pfizer Inc. (PFE.N) $37.20 +0.74
Novartis AG (NOVN.S) CHF83.80 -0.05
Merck & Co., Inc. (MRK.N) $56.24 +0.23
Roche Holding Ltd. (ROG.S) CHF244.10 +2.40
Roche Holding Ltd. (RO.S) CHF243.40 +0.90
Bayer AG (BAYGn.DE) €106.50 +1.40
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €73.55 -0.22
GlaxoSmithKline plc (GSK.L) 1,295.00 +4.50

Earnings vs. Estimates